-+ 0.00%
-+ 0.00%
-+ 0.00%

Kyverna signs commercial manufacturing, supply deal with ElevateBio for miv-cel CAR-T therapy

PUBT·07/27/2026 12:03:38
Listen to the news
Kyverna signs commercial manufacturing, supply deal with ElevateBio for miv-cel CAR-T therapy
  • Kyverna signed a commercial manufacturing and supply agreement with ElevateBio for miv-cel, covering U.S. commercial production, global clinical supply.
  • Deal targets flexible, scalable capacity ahead of potential launches in stiff person syndrome, generalized myasthenia gravis.
  • ElevateBio cited a clinical manufacturing success rate above 98% for miv-cel across the companies’ three-year partnership.
  • Kyverna reiterated plans to complete a rolling BLA submission for miv-cel in stiff person syndrome in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyverna Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-316916), on July 27, 2026, and is solely responsible for the information contained therein.